RNS Number : 2884N Renalytix PLC 22 September 2023     THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF MAR. THE PERSON RESPONSIBLE FOR ARRANGING THE RELEASE OF THIS ANNOUNCEMENT ON BEHALF OF RENALYTIX IS JAMES MCCULLOUGH , CEO.

RNS Number : 6395L Renalytix PLC 07 September 2023     Renalytix Appoints Senior Executive Howard Doran as Chief Business Officer Doran Brings Significant Diagnostics Sector Experience to Lead the KidneyIntelX Global Sales Effort   LONDON and SALT LAKE CITY -   September 07, 2023 - Renalytix plc

RNS Number : 8461J Renalytix PLC 21 August 2023     THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF MAR. THE PERSON RESPONSIBLE FOR ARRANGING FOR THE RELEASE OF THIS ANNOUNCEMENT ON BEHALF OF RENALYTIX IS JAMES MCCULLOUGH , CEO.

RNS Number : 2096I Renalytix PLC 03 August 2023     Renalytix plc ("Renalytix" or the "Company")   RSU vesting for employees   LONDON and SALT LAKE CITY , August 3, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that 92,770 Restricted Stock Units ("RSUs") previously

RNS Number : 1362I Renalytix PLC 03 August 2023     Renalytix plc ("Renalytix" or the "Company")   Formation of Clinical Advisory Board   Renalytix Clinical Advisory Board Formed to Support Broadening Use of KidneyintelX.dkd  World leading, multi-disciplinary experts advise on adoption of FDA

RNS Number : 7254G Renalytix PLC 21 July 2023     Renalytix plc ("Renalytix" or the "Company")   Middle East Distribution Agreement with Vector Pharma   Commercial availability of kidneyintelX.dkd™ expanded to an estimated 4 million DKD Patients in the Middle East   Distribution agreement opens

RNS Number : 2648G Renalytix PLC 17 July 2023   The following amendment has been made to the ' Issue of Shares' announcement released on 17 July 2023 at 07:00 under RNS No 1495G   The correct figure for the principal remaining under the convertible bond   after the settlement of the repayment is

RNS Number : 1495G Renalytix PLC 17 July 2023   Renalytix plc ("Renalytix" or the "Company")   Issue of Shares   LONDON and SALT LAKE CITY -   July 17, 2023 -   Renalytix plc   (NASDAQ: RNLX) (LSE: RENX) , announces the repayment of $1.06 million of the Company's convertible bond, further details

RNS Number : 2729F Renalytix PLC 07 July 2023     Renalytix plc ("Renalytix" or the "Company")   Late-Breaking KidneyIntelX Evidence Released at 83rd American Diabetes Association Scientific Sessions 12 Months KidneyIntelX™ in vitro prognostic testing continued to demonstrate clinical actions that

RNS Number : 2612F Renalytix PLC 06 July 2023   Renalytix plc ("Renalytix" or the "Company")   Grant of Share Options   LONDON and SALT LAKE CITY -   July 6, 2023 -   Renalytix plc   (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled